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Edited by Peter BrzezinskiAbstract The antitumor drug elsamicin A contains a coumarin-
related chartarin chromophore that intercalates into DNA. It
diﬀers from other related molecules in its disaccharide moiety,
which bears an amino sugar. Its binding to DNA was analyzed
using isothermal titration calorimetry and UV thermal denatur-
ation, and characterized thermodynamically. For the association
of elsamicin A with DNA we found DG ¼ 8:6 kcal mol1,
DH ¼ 10:4 kcal mol1, DS ¼ 6:1 cal mol1 K1, and
K obs ¼ 2:8ð%0:2Þ  106 M1 at 20 C in 18 mM Naþ. The
contributions to the free energy of binding that lead to the DNA–
elsamicin complex are compared with the binding to DNA of
chartreusin, another chartarin-containing drug. The results are
discussed in terms of the contributions of the disaccharide
moieties into the strength of binding.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The interaction of small ligands like antitumour drugs, with
DNA sequences or structures is the focus of considerable re-
search. Understanding DNA–drug interactions requires not
only knowledge of the structures, but also a detailed thermo-
dynamic characterization of free energy contributions to the
interaction between DNA and ligands [1–5]. The energetic
characterization of drug binding to DNA provides new in-
sights into DNA–drug interactions [1,3,4] and this, together
with structural studies, may be used in rational drug design [6].
We aimed to shed some light on a group of antitumor
drugs containing the coumarin-related chromophore charta-
rin but diﬀerent sugar moieties. These drugs can be consid-
ered a paradigm of intercalating molecules, in which
disaccharide moieties could change sequence-binding prefer-
ences and alter the strength of binding to DNA. Elsamicin A
and chartreusin (Fig. 1) are well-characterized members of
this group [7]. Binding to DNA is believed to be central to
the mechanism by which these drugs exert their antitumoral
eﬀects [7] and the drug-binding sites have been mapped in
DNA regions containing CpG steps [7–9]. Both the rate and* Corresponding author. Fax: +34-93-403-4979.
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doi:10.1016/j.febslet.2004.08.063the extent of the B-to-Z transition were reduced by elsamicin
A, in conditions that would otherwise favor the left-handed
conformation [10]. Moreover, elsamicin A alters the interac-
tion of the Sp1 factor with DNA, and it inhibits the tran-
scription from the P1 promoter of c-myc in vitro [11].
Elsamicin A has broad-spectrum of activity against various
tumors, in which it is more potent than chartreusin in terms of
minimum eﬀective dose [7,12], and it is undergoing phase II
clinical trials [13]. The structure of elsamicin A and related
drugs stimulated interest in both natural and semi-synthetic
analogs, which may have much better pharmacological proﬁles
[7,14]. One such analog, IST-622, is under clinical trials in
Japan [15].
Despite the pharmacological interest of elsamicin A, there is
no experimental data on elsamicin complexes with DNA in the
crystalline state. This shortcoming has been partially met by a
thorough theoretical study [16], which provided some details
about the DNA–drug interactions. Among charteusin analogs,
A132 (30,40-O-exobenzilidene chartreusin) [14] has been crys-
tallized, and the A132–DNA complex was modeled to study
the role of the digitalose sugar moiety in DNA recognition
[17].
We characterize thermodynamically the binding of elsami-
cin A to DNA. An analysis of the binding to DNA of the
related drug chartreusin has been reported elsewhere [18].
The data we have obtained from the analyses of drug binding
to DNA are used to dissect some components of the free
energy of binding, and to compare the contribution of the
various disaccharide moieties to the strength of binding, in
the pursuit of rational drug design of new chartarin-con-
taining drugs.2. Materials and methods
2.1. Materials
Elsamicin A was a gift of Bristol-Myers Squibb. Salmon testes DNA
(Sigma) was sonicated, phenol extracted twice, and dialyzed against 10
mM cacodylate buﬀer (pH 7.0) containing 8 mM NaCl and 0.1 mM
EDTA ([Naþ]¼ 18 mM). DNA concentration, in base pairs, was de-
termined spectrophotometrically at 260 nm using a molar extinction
coeﬃcient of 12 824 M1 cm1.
2.2. Diﬀerential scanning calorimetry (DSC)
Diﬀerential scanning calorimetry (DSC) measurements of the en-
thalpy of salmon testes DNA melting were performed using a Microcal
MC-2 Scanning Calorimeter (Microcal Inc.) as described in detail
elsewhere [18].blished by Elsevier B.V. All rights reserved.
Fig. 1. Structures of the chartarin-containing drugs elsamicin A and
chartreusin.
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titration calorimetry (ITC)
Experiments were carried at 20 C using a Microcal MCS-ITC cal-
orimeter (Microcal Inc., Northampton, MA). The Origin software
(Microcal) was used for data acquisition and analysis. In a typical
experiment, 1.34 ml of a 0.75 mM (bp) DNA in 10 mM cacodylate
buﬀer (pH 7.0) containing 8 mMNaCl and 0.1 mM EDTA ([Naþ]¼ 18
mM) was titrated using a 50 lM elsamicin A solution in the same
buﬀer (10–15 injections of 10 ll each), using a 250 ll syringe rotating at
400 rpm. The injection time was 25 s, and the delay between injections
was 2.5 min. The peaks produced during titration were converted to
heat output per injection by integration and correction for the cell
volume and sample concentration. Binding enthalpies for elsamicin
were determined from the heats of reaction obtained after each injec-
tion to obtain multiple estimates of DH  without any ﬁtting bias. Using
a high DNA concentration ensured that all the titrated drug was ef-
fectively bound after each addition [19,20]. The enthalpy due to drug
dilution was determined by 15 serial injections of elsamicin A solution
into the reaction cell loaded with buﬀer alone, and the values averaged.
It was subtracted from the DH value determined for titration into
DNA to render a corrected value for the binding-induced enthalpy
change DHb [19].
2.4. Determination of binding constants by DNA ultraviolet-melting
analysis
Proﬁles of absorbance at 260 nm versus temperature were measured
between 25 and 98 C, at a heating rate of 0.5 C min1, in the presence
of diﬀerent concentrations of NaCl, in 10 mM cacodylate buﬀer (pH
7.0) and saturating concentrations of elsamicin A (20 lM DNA (bp);
10 lM elsamicin A), using a Shimadzu UV-2101PC spectrophotometer
equipped with a Shimadzu SPR-8 temperature controller.
DNA melting temperatures (Tm) were used to calculate the binding
constant to salmon DNA at the DNAmelting temperature (KTm ), using
the equation derived by Crothers [21]:
1=T m  1=Tm ¼ ðR=nDHwcÞ lnð1þ KTmaÞ ð1Þ
where T m is the UV-melting temperature of salmon testes DNA alone,
Tm is the melting temperature in the presence of saturating amounts of
the drug, DHwc is the enthalpy of DNA melting obtained by DSC, R is
the gas constant, KTm is the drug binding constant at Tm, a is the free
drug activity, which is estimated by one half of the total drug con-
centration, and n is the size of the drug binding site.
The calculated apparent binding constant at Tm can be extrapolated
to a reference temperature using the standard relationship:
d½lnðKobsÞ=dð1=T Þ ¼ ðDHb=RÞ ð2Þ
where Kobs is the DNA binding constant of the drug at the reference
temperature T (Kelvin) and DHb the binding enthalpy, which was di-
rectly determined by ITC.
2.5. Electrostatic contributions in elsamicin A binding to DNA
The eﬀects of diﬀerent NaCl concentrations upon the binding con-
stant of elsamicin A was calculated from the spectrophotometric UV-
melting proﬁles, as described above, and used to determine the ionicstrength dependence of the equilibrium binding constants, at 20 C,
according to the polyelectrolyte theory of Record et al. [22]. The ob-
served linear dependence is described by the relationship:
SK ¼ d logK=d log½Naþ ¼ Zw ð3Þ
where w is the fraction of sodium counterion associated per DNA
phosphate (w ¼ 0:88 for B-DNA), and Z is the apparent charge of the
drug. The quantity SK is equivalent to the number of counterions
released upon binding of the ligand with net charge Z.
Moreover, Zw can be used to evaluate the polyelectrolyte contri-
bution to the free energy of binding to salmon testes DNA following
the equation [22]:
DGpe ¼ ZwT ln½Naþ ð4Þ
and the DGpe obtained (Table 2) allows us to calculate DGt: the ‘non-
polyelectrolyte’ (non-electrostatic) contribution to binding [23] ac-
cording to:
DGobs ¼ DGt þ DGpe ð5Þ3. Results and discussion
The enthalpy of salmon testes DNA melting was deter-
mined by DSC (Fig. 2A). Eq. (1) was used to obtain the
elsamicin A binding constant at the DNA melting temper-
ature, considering the enthalpy of DNA melting together
with the results of DNA ultraviolet melting studies in the
presence of saturating concentrations of the drug and dif-
ferent salt concentrations (Figs. 2B and C and Table 1). A
value of n¼ 3 for elsamicin A was used in Eq. (1), based on
the size of the drug binding-site determined by molecular
dynamics [16]. Experimentally, a Job plot analysis has
shown a binding mode corresponding to 3 mol of DNA per
mol of the structurally related chartreusin [18]. Correction of
the observed binding constant to lower temperatures re-
quires knowledge of the binding enthalpy, which we deter-
mined by ITC (Fig. 3).
Fig. 3A shows representative primary data from the ITC
titration of elsamicin A into salmon testes DNA at 20 C. A
distribution of binding enthalpy estimates was obtained from
three independent titrations and the diﬀerent values averaged
(Fig. 3B). The DHb measured by ITC (DHb ¼ 10:4ð0:3Þ kcal
mol1, at 20 C) was used in Eq. (2) to calculate the binding
constant for the elsamicin–DNA interaction (Kobs ¼ 2:8ð0:2Þ
106 M1, at 20 C). This direct determination of DHb has the
advantage that it does not require to assume that DHb was
constant with the temperature [18,20,24].
The experimental Kobs and the binding enthalpy for elsa-
micin binding to DNA, permitted to obtain complete thermo-
dynamic proﬁles. Table 2 shows the free energy of binding,
which was obtained from the standard equation
DG ¼ RT lnKobs and the entropy calculated using the stan-
dard thermodynamic relationship: DS ¼ ðDGþ DHÞ=T .
The favorable free energy of binding (DGobs ¼ 8:6ð0:1Þ kcal
mol1 at 20 C) was derived from a large negative enthalpic
contribution (DHb ¼ 10:4ð0:3Þ kcal mol1) but was op-
posed by the entropic contribution (DS ¼ 6:1ð0:8Þ cal
mol1 K1). For the easy of comparison, Table 2 also shows
thermodynamic parameters for chartreusin binding to DNA,
which we had determined previously [18]. The entropy term is
favorable for the interaction of chartreusin and unfavorable for
elsamicin A (Table 2). This may be due to increased bonding,
including H-bonds formed by the amino sugar of elsamicin
[16], which produced a loss in translational and rotational
Fig. 2. (A) DSC curve of salmon testes DNA (excess of heat capacity plotted as a function of temperature). Tm: 74.4(0.3) C, DHwc: 8.8(0.2) kcal
mol1. The estimated error is the standard deviation of the mean (three experiments). (B) Examples of UV-melting proﬁles at 260 nm of salmon testes
DNA and its complexes with elsamicin A. Experiments in the presence of the drug were performed in conditions that ensured complete saturation of
DNA (20 lMDNA (bp) plus 10 lM elsamicin A). DNA melting curves correspond to the following salt concentrations: (a) 18 mM Naþ (b) 30 mM
Naþ (c) 18 mM Naþ, in the presence of saturating concentrations of elsamicin, (d) 30 mM Naþ, in the presence of saturating concentrations of
elsamicin. A compilation of the DNA melting results is shown in Table 1. (C) Diﬀerential melting curves for the elsamicin–DNA complexes at 18 nM
Naþ (straight line) and 30 Naþ (dashed line) in the presence of suﬃcient ligand to ensure the saturation of the DNA lattice. A unique melting
transition is observed.
Table 1
UV-melting temperatures of DNA and DNA saturated with elsamicin A under diﬀerent salt conditionsa
[Naþ] mM T m (C) Tm (C) KTm (M1) Kobs (M1)
8 69.0 85.4 9.9(0.5)105 5.2(0.3)106
18 74.4 86.6 5.4(0.3)105 2.8(0.2)106
30 80.0 90.1 3.7(0.2)105 1.9(0.1)106
60 85.8 92.4 1.9(0.1)105 1.0(0.1)106
120 92.6 97.0 1.1(0.1)105 5.7(0.2)105
a Salt dependence of the binding constants at the melting temperature (KTm ), and at 20 C (Kobs) for elsamicin A binding to DNA. T m is the UV-
melting temperature of salmon testes DNA alone, Tm is the melting temperature in the presence of saturating amounts of elsamicin (Fig. 2). KTm the
drug binding constant at Tm and Kobs drug binding constant determined at 20 C (mean valuesS.D.), were calculated using Eqs. (1) and (2) as
described in the main text. For application of Eq. (2) the elsamicin binding enthalpy, DHb at 20 C was used (Fig. 3 and Table 2).
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a tight binding to DNA, as discussed below.
Fig. 4 shows the dependence of the DNA-binding constant
of elsamicin A and chartreusin on salt concentration. The
salt-dependent changes in the binding constant were used,
according to the polyelectrolyte theory [22], to calculate the
‘actual’ charge of the ligands and the salt dependence of
the binding constant using Eqs. (3) and (4). For elsamicin, the
slope (SK) of the double logarithmic Record’s plot in Fig. 4
was )0.82 (Table 2), which is equivalent to the number of
counterions released upon drug binding, and corresponds to a
calculated apparent change (Z¼+0.93) consistent with the
positive charge carried by elsamicin at neutral pH (Fig. 1).
The binding constant of elsamicin A decreased with increas-
ing salt concentrations and the binding was thermodynami-
cally linked to the release of counterions bound to DNA.
However, the binding constant for the uncharged chartreusinvaried only slightly with salt concentrations (Fig. 4), and it
was accompanied by a rather low counterion release [18],
which is consistent with the absence of net charge in this
molecule (Fig. 1).
The observed free energy was partitioned into the non-
electrostatic (DGt) and polyelectrolyte (electrostatic) (DGpe)
contributions using Eq. (5). A DGpe of 1.4 kcal mol1 and a
DGt of )7.2 kcal mol1 for elsamicin A indicated that the non-
electrostatic component of binding was fundamental in the
elsamicin–DNA complex (it represented about 85% of the free
energy of binding). DGt was used to compare the ‘non-elec-
trostatic’ contribution to the free energy of binding for both
drugs, which was almost the same (Table 2). For elsamicin, the
polyelectrolyte component of binding increased by about
ﬁvefolds owing to the presence of the charged amino sugar. At
the same time, the charged amino would also anchor the di-
saccharide more snugly into the DNA minor groove [16]. This
Fig. 3. (A) Representative primary data from an isothermal titration
calorimetry experiment, at 20 C, used to obtain multiple estimates of
DH  in a titration of elsamicin A on a large excess of DNA, without
any assumptions regarding the binding model [20]. The enthalpy as-
sociated with elsamicin dilution was averaged from 15 drug injections
into buﬀer, and this value (DHdil ¼ 1:46ð0:11Þ kcal mol1) subtracted
from the raw calorimetric data. (B) Distribution of DNA-binding
enthalpy values obtained after integration of peaks and normalization
for the total of elsamicin A added per injection. Data accumulated
from three independent isothermal titration calorimetry analyses at 20
C, with 10–15 drug injections in each experiment.
Fig. 4. Salt dependence of elsamicin A and chartreusin binding con-
stants at 20 C. Data are presented according to the Record’s theory
[22]. Elsamicin A (circles) and chartreusin (squares). For the easy of
comparison, data for chartreusin were adapted from [18]. The linear
least-squares ﬁt of the data yields slopes (SK) of )0.82 for elsamicin A
and )0.13 for chartreusin, respectively. From these values, it is esti-
mated that elsamicin A is positively charged, while chartreusin is un-
charged at neutral pH (see the main text for details).
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additional entropic penalty (Table 2), given the loss of mo-
lecular ﬂexibility in both the drug and the DNA, and second,
some favorable van der Waals and hydrophobic contacts, as
well as the presence of additional H-bonding with DNA bases
and phosphates. A main diﬀerence in the hydrophobic con-
tribution to binding can occur because of the removal of water
and counterions from the disaccharide moieties. Several mo-
lecular interactions between either elsamicin A or chartreusin
and DNA have been suggested from molecular dynamics
studies [16,17], which, in the absence of co-crystallographic
structures, is the most reliable representation of DNA–drug
interactions. These interactions should contribute to both
negative enthalpy and entropy [25–27]. A hydroxyl group of
the digitalose sugar of chartreusin (R2 in Fig. 1) has beenTable 2
Comparison of thermodynamic parameters for chartreusin and elsamicin A
Kobs
(M1)
DGobs
(kcal mol1 )
SK DG
(kc
Elsamicin A 2.8(0.2)106 )8.6(0.1) )0.82 )1.
Chartreusin 3.6(0.3)105 )7.4(0.1) )0.13 )0.
aKobs (M1) is the binding constant for the interaction of the ligand with salm
calculated from DGobs ¼ RT lnK. SK is the slope of the plot of log Kobs vers
non-electrostatic contributions to the binding free energy (DGpe ¼ SKRTln
ITC at 20 C (Fig. 3 and [18]). The estimated errors are the standard deviatsuggested to form a H-bond with the guanine 2-amino group
(N-2) and the carbonyl group (O-2) of cytosine in the base pair
on one side of the intercalation site [17], while for elsamicin,
the amino group (R2 in Fig. 1) of the sugar was bonded di-
rectly to one of the phosphates, and it also formed a water
bridge with the adjacent cytosine and guanine [16].
Diﬀerences in the ﬂuorescence spectral characteristics of the
complexes formed by elsamicin A and chartreusin with dif-
ferent deoxyribonucleic acids have indicated a signiﬁcant
participation of the guanine 2-amino and the amino sugar of
elsamicin in DNA–drug interaction [28]. For these structurally
related drugs DGt only diﬀered in 0.1 kcal mol1, which sug-
gests that diﬀerences in molecular interactions with DNA like
hydrogen-bonds that involve the amino group of the sugar of
elsamicin or the hydroxyl group of chartreusin at the same
sugar position (Fig. 1) may contribute equally to the non-
electrostatic strength of binding. In a comprehensive study
about the energetic cost of structural alterations in anthracy-
clines [2] the calculations of DGt for doxorubicin and hy-
droxyrubicin, in which the amino group of the sugar is
replaced by a hydroxyl, showed values that diﬀered by 0.7 kcal
mol1. Taking into account that the error for this type of
determination was estimated to be 0.5 kcal mol1 [2], we ten-
tatively consider that the diﬀerence we observed in the non-
electrostatic part of the binding (DGt ¼ 0:1 kcal mol1) was
mainly due to the distinct H-bonds provided by the amino
group in the R2-position of elsamicin A (Fig. 1). Other non-
bonded drug–DNA interactions may be at the expense of
existing molecular interactions between water and thebinding to salmon testes DNAa
pe
al mol1 )
DGt
(kcal mol1 )
DH
(kcal mol1)
TDS
(kcal mol1)
4 )7.2 )10.4(0.3) )1.8(0.3)
3 )7.1 )7.1(0.2) 0.4(0.1)
on testes DNA in 18 mMNaþ at 20 C. DGobs is the binding free energy
us log[Naþ] shown in Fig. 4. DGpe and DGt are the polyelectrolyte and
[Naþ]) evaluated at 18 mM Naþ. Enthalpy values were determined by
ions of the mean.
72 F. Barcelo, J. Portugal / FEBS Letters 576 (2004) 68–72deoxyribonucleic acid without net gain of H-bonding [16], and
thus basically isoenergetic.
The charged amino group appears to favor both the long-
range and short-range elsamicin–DNA interactions, which can
participate in both direct and indirect H-bonding to DNA [16].
In this context, diﬀerences in the interactions between elsami-
cin or chartreusin and DNA can be used to design new
chartarin-containing molecules with improved DNA-binding
aﬃnity. The role of disaccharide moieties may have implica-
tions for rational drug design, not only because of the disac-
charide binding to DNA studied here, and its eﬀects on drug
solubility [7], but also because the sugar moieties of some
useful antitumor drugs are considered essential in several as-
pects of their biological activity [29].
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